Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, BioXcel Therapeutics, Inc. reported revenue of $1M, down 71.7% year over year. Operating margin was -7860.0% and net margin -10887.4%, on a free-cash-flow margin of -8974.3% with capital expenditure at 0.0% of revenue. Every figure is computed directly from BTAI's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $1M | -7860.0% | -10887.4% |
| FY2024 | $2M | -2967.6% | -2630.1% |
| FY2023 | $1M | -12448.0% | -12974.9% |
| FY2022 | $0M | -42572.0% | -44201.9% |
| FY2021 | n/a | n/a | n/a |
How does BTAI compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.